Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

SML3050

Sigma-Aldrich

Olsalazine sodium

Synonym(s):

Olsalazine sodium, 3,3´-Azobis(6-hydroxybenzoic acid) sodium, 5,5′-Azodisalicylic acid sodium, 5,5′-azobis(salicylic acid) sodium, C.I. Mordant Yellow 5; 3,3′-dicarboxy-4,4′-dihydroxyazobenzene sodium, azodisal sodium

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C14H8N2O6 · 2Na
CAS Number:
Molecular Weight:
346.20
UNSPSC Code:
12352200
NACRES:
NA.24

assay

≥98% (HPLC)

Quality Level

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

2-8°C

InChI

1S/C14H10N2O6.2Na/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22;;/h1-6,17-18H,(H,19,20)(H,21,22);;/q;2*+1/p-2/b16-15+;;

Biochem/physiol Actions

Olsalazine is an anti-inflammatory drug used in inflammatory bowel disease and ulcerative colitis treatments. It is a pro-drug of 5-aminosalicylic acid (mesalamine) that it is converted by the bacteria in the colon to mesalamine. Olsalazine (5-aminosalicylic acid) is consider as a broad-spectrum anticancer agent. Additionally, olsalazine increases both eEF1A2 and utrophin A levels in in C2C12 myoblasts (relevant to Duchenne muscular dystrophy).

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Amany A Abdin et al.
Journal of Crohn's & colitis, 2(4), 296-303 (2008-12-01)
Traditional medical treatments for ulcerative colitis (UC) are still compromised by its adverse effects and not potent enough to keep in remission for long-term periods. So, new therapies that are targeted at specific disease mechanisms have the potential to provide
Sandra Cortez-Maya et al.
Biomolecules, 9(8) (2019-08-16)
Improving the activity and selectivity profile of anticancer agents will require designing drug carrier systems that employ soluble macromolecules. Olsalazine-PAMAM-dendrimer-salicylic acid-conjugates with dendritic arms of different lengths have shown good stability regarding the chemical link between drug and spacer. In

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service